GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
Japanese Yen Nears Seven-Month High as Oil Approaches $100 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Huawei Launches Mate XT2 Foldable Phone in China 
3 clinical-grade skincare creams you really shouldn’t buy online 
White House Weighs Refined Copper Tariffs as Cost Concerns Grow 
UK Food Inflation Forecast to Hit 6.4% by Mid-2027 
TSMC August Revenue Jumps 53% on AI Chip Demand 
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit 
Treasury Buyback Fails to Cool Long-Term Yields 
Enflame Shares Surge 200% in Shanghai AI Chip Debut 
China Inflation Accelerates in August as CPI, PPI Rise 
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates 
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities 
Add as a preferred source on Google
US pharmaceutical giant Eli Lilly would cut the cost of its insulin by 70 percent through a series of steps, such as capping out-of-pocket costs at $35 per month for people with insurance.
However, while the US$35 cap takes effect immediately, other measures will be implemented later in the year.
According to the Indianapolis-based Lilly, they are taking actions to make it easier for Americans to access their insulin and help those having ”difficulty navigating a complex healthcare system."
US president Joe Biden called on other pharmaceutical firms to follow suit, noting that it's “flat wrong” to force Americans to pay over $300 for insulin, which costs less than $10 to make.
A centerpiece is the 70 percent price drop in Humalog, Lilly's most commonly prescribed insulin.
According to a 2020 Rand Corporation study, Insulin prices in the US have soared 8 times more than in 32 comparable high-income countries.
But much of the bounty from lofty prices do not go to pharma firms but is passed on to health insurers in the form of rebates.
